Key Cash Flow and Balance-Sheet Trends Signals for Neogen (NASDAQ:NEOG)

  • Neogen (NASDAQ:NEOG) reported fiscal first-quarter 2027 Revenue of USD 222.8 million on October 6, 2026, representing an increase of 6.5 percent and 8.1 percent on a core basis, above its guidance range of USD 207 million to USD 209 million.
  • Adjusted EPS was USD 0.08 versus USD 0.04, while the GAAP net loss was USD 11.9 million, or USD 0.05 per share. Adjusted EBITDA was USD 41.6 million, an 18.7 percent Margin versus 17.0 percent, against guidance of about USD 37 million.
  • Management raised fiscal 2027 guidance to revenue of USD 885 million to USD 890 million, from USD 880 million to USD 885 million, and adjusted EBITDA of USD 181 million to USD 183 million, from USD 180 million to USD 182 million.
  • Free cash flow was USD 4.7 million, and USD 20.0 million of Debt was repaid. Food Safety revenue climbed 7.4 percent to USD 163.2 million and Animal Safety climbed 4.2 percent to USD 59.6 million, with growth in every region.

Takeover Interest and Deal Risk: Outlook Implications for Neogen (NASDAQ:NEOG)

Core growth of 8.1 percent included about 3 percent from distributor inventory adjustments in the prior-year quarter and the timing of customer orders, so underlying growth is nearer 5 percent, simple arithmetic. Gross margin was 47.4 percent versus 45.4 percent, while adjusted gross margin was 49.8 percent. Indicator Testing and Culture Media, including Petrifilm, climbed to USD 85.6 million from USD 76.8 million, and Bacterial and General Sanitation to USD 44.6 million from USD 41.6 million.

Takeover Interest and Deal Risk: Key Business Impact on Neogen (NASDAQ:NEOG)

The prior-year quarter's USD 36.3 million GAAP profit included a USD 76.4 million gain on selling the Cleaners and Disinfectants business, so the year-on-year GAAP swing is not operational. Interest expense of USD 13.8 million on USD 774.2 million of non-current debt keeps GAAP Earnings negative. This quarter's adjustments include USD 22.3 million of Acquisition intangible amortization, USD 5.6 million of duplicate Petrifilm Manufacturing costs and USD 5.1 million of transformation costs.

Risks From Revenue, Earnings and Guidance for Neogen (NASDAQ:NEOG)

The sale of its Genomics business to Zoetis is projected to conclude by the end of December 2026, pending regulatory reviews. Neogen begins a multi-quarter transition of Petrifilm manufacturing to Lansing in November 2026, after fully validating its first product unit in August. The company has not confirmed a second-quarter report date. Guidance implies about USD 221 million to USD 222 million of revenue per quarter for the remaining three quarters, simple arithmetic, so order timing must not reverse.

Neogen (NASDAQ:NEOG) After the Latest Revenue, Earnings and Guidance Update

Yes on momentum, with caveats. But roughly 3 points of core growth came from timing, GAAP results remain negative on amortization and interest, and the Petrifilm transition adds execution risk. The next catalysts are the November Petrifilm transition and the Genomics sale closing. Neogen (NASDAQ:NEOG) beat the top of its revenue guidance by about USD 13.8 million, raised full-year targets and generated USD 41.6 million of adjusted EBITDA. The balance favors improving fundamentals that still need proof. Investors should watch whether first-quarter order timing reverses in later quarters.